Expert.ai Introduces New AI Solutions to Accelerate Pharma & Life Sciences Innovation

Unveiled at BioTechX Europe 2025, the new solutions are purpose-built to accelerate research, clinical trial design and regulatory processes.

ROCKVILLE, Md. and BASEL, Switzerland, Oct. 6, 2025 /PRNewswire/ -- Expert.ai, a leading provider of enterprise artificial intelligence solutions for business value creation, today announced the debut of its new AI-powered offerings designed to accelerate innovation across the pharmaceutical, healthcare and life sciences industries. Launched at BioTechX Europe 2025, Europe's largest congress dedicated to pharma & healthcare, the new solutions enable organizations to enhance data analysis, streamline discovery processes and unlock new possibilities for clinical trials and therapeutic improvement:

EIX-Submission Readiness empowers teams to build smarter, more efficient workflows for regulatory documentation.

EIX-Preclinical Document Intelligence streamlines preclinical documentation with greater speed and accuracy, freeing experts to focus on innovation.

EIX-Clinical Trials Intelligence helps research teams to distill the most accurate, up-to-date information by disambiguating across mountains of content from clinical registries, scientific publications and real-world data.  

EIX-IP Detection delivers comprehensive, explainable insights across patents, scientific literature and clinical trial data.

Leveraging its deep domain expertise and unique hybrid AI approach, Expert.ai helps researchers transform the complexity of research & development into strategic advantage. By reducing manual effort and scaling insights from massive volumes of data, the new solutions use the most effective AI techniques to ensure regulatory accuracy, improve trial design, accelerate patient recruitment, reduce costs and minimize the constant risks of delays.

"We're extremely proud of this new offering for Pharma & Life Sciences, which represents a significant advancement in our mission to harness AI for meaningful impact in these industries," said Christophe Aubry, Global Head of Life Sciences & Healthcare, Expert.ai. "Our enhanced solutions are designed to reduce complexity, enhance scientific and regulatory accuracy, and free experts to focus on innovation where it matters most. By bringing automation, explainability, and traceability to every step—from research documentation to submission readiness—we enable smarter, faster, and compliant decision-making."

With these innovations, Expert.ai continues to set the standard for applying AI in Pharma & Life Sciences, delivering greater efficiency and reliability across the life sciences value chain through intelligent document automation and AI agents.

For more information about the Expert.ai solutions, available through EidenAI Suite, visit Pharma – Accelerating Research with AI | expert.ai

About Expert.ai
Expert.ai is a company specializing in the implementation of enterprise artificial intelligence solutions to create business value, listed on the Euronext Growth Milan market (EXAI:IM). Through EidenAI Suite, expert.ai supports companies and public administrations in their AI adoption journeys by offering a suite of ready-to-use solutions tailored for vertical markets. With 30 years of pioneering experience in innovation and technological excellence, expert.ai has successfully implemented hundreds of projects, integrating the best technologies available on the market with its proprietary solutions. Its Hybrid AI approach (a neuro-symbolic AI based on natural language understanding and knowledge graphs, and machine learning/deep learning techniques - large language models, generative AI and agentic AI) is grounded in a vision of responsible, transparent and sustainable AI designed to serve people, address key challenges and achieve meaningful goals. With a global presence in Europe and North America, we proudly serve directly and through partners Fortune 1000 clients around the world.

For more information: https://www.expert.ai/

SOURCE expert.ai